DBV Technologies Joins CAC Mid 60 and SBF 120 Indices
Event summary
- DBV Technologies added to CAC Mid 60 and SBF 120 indices effective March 23, 2026.
- Inclusion follows Euronext Paris annual review completed March 12, 2026.
- Company focuses on food allergy treatments using VIASKIN® patch technology.
- Shares traded on Euronext Paris and Nasdaq Capital Market.
The big picture
DBV’s inclusion in the CAC Mid 60 and SBF 120 indices signals recognition of its progress in the biopharmaceutical sector, particularly in addressing unmet medical needs in food allergies. The move comes as mid-cap indices increasingly attract institutional investors seeking growth opportunities in specialized healthcare segments. The company’s proprietary VIASKIN® technology positions it as a key player in epicutaneous immunotherapy, a field with significant potential for innovation.
What we're watching
- Market Visibility
- How index inclusion will impact DBV’s visibility among European investors ahead of potential commercialization.
- Commercialization Timing
- The pace at which DBV can advance its VIASKIN® patch through clinical trials and regulatory approvals.
- Investor Sentiment
- Whether broader market trends will sustain interest in mid-cap biopharmaceutical stocks.
Related topics